Blood Samples to Identify Biomarkers in Haploidentical Graft Recipients

Fred Hutchinson Cancer Center1 site in 1 country11 target enrollmentMay 2010

ConditionsLeukemia Hodgkin Disease Non-Hodgkin Lymphoma Myelodysplastic Syndrome Multiple Myeloma

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Leukemia
Sponsor: Fred Hutchinson Cancer Center
Enrollment: 11
Locations: 1
Primary Endpoint: Donor T-cell chimerism
Status: Completed
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The investigators are interested in identifying patient-specific factors related to donor chimerism in patients who receive nonmyeloablative hematopoietic stem cell transplants from haploidentical donors. We will look how patients' bodies break down and immediately respond to cyclophosphamide, fludarabine and mycophenolate mofetil.

Registry

clinicaltrials.gov

Start Date

May 2010

End Date

December 2011

Last Updated

2 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Fred Hutchinson Cancer Center

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Scheduled to receive nonmyeloablative conditioning which includes fludarabine
•Scheduled to receive a haploidentical graft
•Scheduled to receive postgrafting immunosuppression which includes oral mycophenolate mofetil (MMF) or enteric-coated mycophenolic acid
•Age \>18 years at the time of enrollment